Literature DB >> 32052838

Physical Illnesses Before Diagnosed as Schizophrenia: A Nationwide Case-Control Study.

Yi-Lung Chen1,2, Chun-Hung Pan2,3, Chi-Kang Chang2, Pao-Huan Chen4,5, Hu-Ming Chang2, Ming-Hong Tai1,6, Sheng-Shiang Su2, Shang-Ying Tsai4,5, Chiao-Chicy Chen4,7,8, Chian-Jue Kuo2,4,5.   

Abstract

Some physical illnesses are potentially associated with the development of schizophrenia. However, few studies have investigated these associations. Here, we examined physical illnesses and medical utilization patterns existing before patients received a diagnosis of schizophrenia. We enrolled a large representative cohort of the general population in Taiwan (N = 1 000 000) and identified 1969 young patients with a new diagnosis of schizophrenia from January 1, 2000 to December 31, 2013. We conducted a nested case-control study based on risk-set sampling. Each case was age-matched and sex-matched with 4 controls selected from the general population. The case and control groups were compared on the basis of various clinical characteristics. Conditional logistic regression was used to estimate the magnitude of risk associated with newly diagnosed schizophrenia. Within the 1 year before the schizophrenia diagnosis, the cases were most likely to visit the psychiatry department, followed by internal medicine and family medicine departments. According to multivariate analysis, compared with the controls, the cases had substantially higher risk of physical conditions in the prodromal phase, including hypertension (adjusted risk ratio [aRR] = 1.93, P = .001), other forms of heart disease (aRR = 2.07, P < .001), cerebrovascular diseases (aRR = 2.96, P = .001), chronic obstructive pulmonary disease (aRR = 1.50, P = .005), asthma (aRR = 1.76, P = .003), and irritable bowel syndrome (aRR = 2.00, P < .001). A wide range of psychiatric diseases and concomitant use of medications were significantly associated with schizophrenia development. In conclusion, several physical illnesses were identified to be associated with schizophrenia development, indicating that people with these illnesses could be vulnerable to schizophrenia.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  control study; medical utilization; nested case; physical comorbidities; psychiatric comorbidity; schizophrenia

Mesh:

Year:  2020        PMID: 32052838      PMCID: PMC7342094          DOI: 10.1093/schbul/sbaa009

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  45 in total

Review 1.  Physical health and schizophrenia.

Authors:  Alex J Mitchell; Darren Malone
Journal:  Curr Opin Psychiatry       Date:  2006-07       Impact factor: 4.741

Review 2.  Regulation of the HPA axis by cytokines.

Authors:  A V Turnbull; C Rivier
Journal:  Brain Behav Immun       Date:  1995-12       Impact factor: 7.217

Review 3.  The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness.

Authors:  Joseph Firth; Najma Siddiqi; Ai Koyanagi; Dan Siskind; Simon Rosenbaum; Cherrie Galletly; Stephanie Allan; Constanza Caneo; Rebekah Carney; Andre F Carvalho; Mary Lou Chatterton; Christoph U Correll; Jackie Curtis; Fiona Gaughran; Adrian Heald; Erin Hoare; Sarah E Jackson; Steve Kisely; Karina Lovell; Mario Maj; Patrick D McGorry; Cathrine Mihalopoulos; Hannah Myles; Brian O'Donoghue; Toby Pillinger; Jerome Sarris; Felipe B Schuch; David Shiers; Lee Smith; Marco Solmi; Shuichi Suetani; Johanna Taylor; Scott B Teasdale; Graham Thornicroft; John Torous; Tim Usherwood; Davy Vancampfort; Nicola Veronese; Philip B Ward; Alison R Yung; Eoin Killackey; Brendon Stubbs
Journal:  Lancet Psychiatry       Date:  2019-07-16       Impact factor: 27.083

Review 4.  Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention.

Authors:  P Fusar-Poli; A R Yung; P McGorry; J van Os
Journal:  Psychol Med       Date:  2013-02-18       Impact factor: 7.723

Review 5.  Hypertension and cardiovascular risk: General aspects.

Authors:  Sverre E Kjeldsen
Journal:  Pharmacol Res       Date:  2017-11-07       Impact factor: 7.658

6.  Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment.

Authors:  C Song; Z Merali; H Anisman
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

7.  Kynurenine pathway in psychosis: evidence of increased tryptophan degradation.

Authors:  Sandra Barry; G Clarke; P Scully; T G Dinan
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

Review 8.  Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis.

Authors:  Rachel Upthegrove; Nuria Manzanares-Teson; Nicholas M Barnes
Journal:  Schizophr Res       Date:  2014-04-04       Impact factor: 4.939

Review 9.  Does tobacco use cause psychosis? Systematic review and meta-analysis.

Authors:  Pedro Gurillo; Sameer Jauhar; Robin M Murray; James H MacCabe
Journal:  Lancet Psychiatry       Date:  2015-07-09       Impact factor: 27.083

10.  Asthma, corticosteroid use and schizophrenia: A nationwide population-based study in Taiwan.

Authors:  Wei-Chen Wang; Mong-Liang Lu; Vincent Chin-Hung Chen; Mei-Hing Ng; Kuo-You Huang; Ming-Hong Hsieh; Meng-Jer Hsieh; Roger S McIntyre; Yena Lee; Charles Tzu-Chi Lee
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

View more
  8 in total

1.  Clustering of physical health multimorbidity in people with severe mental illness: An accumulated prevalence analysis of United Kingdom primary care data.

Authors:  Naomi Launders; Joseph F Hayes; Gabriele Price; David Pj Osborn
Journal:  PLoS Med       Date:  2022-04-20       Impact factor: 11.069

2.  Diagnostic progression to schizophrenia in 35,255 patients with obsessive-compulsive disorder: a longitudinal follow-up study.

Authors:  Mu-Hong Chen; Shih-Jen Tsai; Chih-Sung Liang; Chih-Ming Cheng; Tung-Ping Su; Tzeng-Ji Chen; Ya-Mei Bai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-03-24       Impact factor: 5.270

Review 3.  Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness.

Authors:  Victor Mazereel; Johan Detraux; Davy Vancampfort; Ruud van Winkel; Marc De Hert
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-09       Impact factor: 5.555

4.  Prevalence of Major Cardiovascular Disease Events Among People Diagnosed With Schizophrenia Who Have Sleep Disturbance, Sedentary Behavior, or Muscular Weakness.

Authors:  Alexandra Berry; Alison R Yung; Matthew J Carr; Roger T Webb; Darren M Ashcroft; Joseph Firth; Richard J Drake
Journal:  Schizophr Bull Open       Date:  2021-01-19

5.  Exploring the Relationship Between Schizophrenia and Cardiovascular Disease: A Genetic Correlation and Multivariable Mendelian Randomization Study.

Authors:  Rada R Veeneman; Jentien M Vermeulen; Abdel Abdellaoui; Eleanor Sanderson; Robyn E Wootton; Rafik Tadros; Connie R Bezzina; Damiaan Denys; Marcus R Munafò; Karin J H Verweij; Jorien L Treur
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

6.  Altered Autonomic Function in Individuals at Clinical High Risk for Psychosis.

Authors:  Anna Kocsis; Ruchika Gajwani; Joachim Gross; Andrew I Gumley; Stephen M Lawrie; Matthias Schwannauer; Frauke Schultze-Lutter; Tineke Grent-'t-Jong; Peter J Uhlhaas
Journal:  Front Psychiatry       Date:  2020-11-06       Impact factor: 4.157

7.  Examining healthcare professionals' beliefs and actions regarding the physical health of people with schizophrenia.

Authors:  Alexandra Berry; Richard J Drake; Alison R Yung
Journal:  BMC Health Serv Res       Date:  2020-08-20       Impact factor: 2.655

8.  Association between cognitive impairment and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia.

Authors:  Wenwang Rao; Yunshu Zhang; Keqing Li; Xiang Yang Zhang
Journal:  Aging (Albany NY)       Date:  2021-06-16       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.